{
    "medicine_id": "a336dc324b4ba818ebfa843a2dbc6f6bb734940d",
    "platform_id": "DB06771",
    "metadata": {
        "name": "Besivance 6 mg 1mL Suspension",
        "composition": "6 mg 1mL Besifloxacin",
        "clinical_particulars": {
            "therapeutic_indications": "Treatment of bacterial conjunctivitis Bacterial isolates that are susceptible to besifloxacin include CDC coryneform group G Corynebacterium pseudodiphtheriticum Corynebacterium striatum Haemophilus influenzae Moraxella lacunata Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis Staphylococcus lugdunensis Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius",
            "contraindications": {
                "disease": "LD50 rat 2000 mg kg The most common adverse reaction reported in 2 of patients treated with besifloxacin was conjunctival redness",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Besifloxacin tear concentrations were higher than MIC90 minimum inhibitory concentration values for common bacterial pathogens and sustained for 24 hours or longer Mean residence time in the conjunctiva was 4 7 hours",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Besifloxacin"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Besifloxacin may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Besifloxacin"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Hydroxyzine"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB14513",
                        "description": "Magnesium can cause a decrease in the absorption of Besifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The therapeutic efficacy of Vibrio cholerae CVD 103 HgR strain live antigen can be decreased when used in combination with Besifloxacin"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Besifloxacin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}